Quantum BioPharma Ltd (QNTM)

The Quest to Repair What Multiple Sclerosis Takes AwayJune 24, 2026 9:00 AM
InvestorsHub NewsWireThe Quest to Repair What Multiple Sclerosis Takes AwayBioMedWire Editorial Coverage: Multiple sclerosis ("MS") gradually strips people of command over their own bodies, advancing steadily with no available cure. More than 2.9 million people across the globe are currently living with the disease. But even with generations of scientific study and research, every approved treatment still falls short of one essential objective: bringing the disease to a complete stop. Existing therapies can slow its advance, but none can halt it outright. That shortfall translates into a future of mounting disability for millions of MS sufferers. Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) (Profile) is determined working to change that outcome. The company is developing Lucid-MS, a patented, first-in-class drug candidate that approaches the disease from an entirely different angle by directly targeting the myelin sheath that MS destroys; the potential treatment is now preparing to move into phase 2 clinical trials. Quantum BioPharma stands among a group of companies pursuing therapies for neurological, autoimmune and immune-mediated conditions, a group that also includes Novartis AG (NYSE: NVS), Merck & Co. Inc. (NYSE: MRK), TG Therapeutics Inc. (NASDAQ: TGTX) and Bristol Myers Squibb Company (NYSE: BMY).Multiple sclerosis is especially destructive because of its tendency to worsen progressively.Instead of working through the immune system, Quantum BioPharma's Lucid-MS acts directly on the myelin sheath.The scientific case behind Lucid-MS rests on years of disciplined research.Quantum BioPharma has finished dosing in both 180-day, repeated-dose oral toxicity and toxicokinetic studies for Lucid-21-302.Click here to view the custom infographic of the Quantum BioPharma editorial.A Disease That Erodes Movement, IndependenceMultiple sclerosis is a long-term inflammatory condition affecting the central nervous system. In MS, the immune system mistakenly attacks the brain and spinal cord, damaging myelin, the protective coating around nerve fibers that allows electrical impulses to travel efficiently. As myelin breaks down, these signals slow, falter or fail altogether, resulting in a mix of symptoms that can include tingling, vision disturbances, mobility difficulties, cognitive decline and, over time, a progressive erosion of physical control.MS does not spare any age group. The worldwide average age at diagnosis is 32, with an estimated 1.5% of all those with MS diagnosed before turning 18. Women receive an MS diagnosis at twice the rate of men. Within the United States alone, close to one million people are currently living with the disease in the United States, a number that more than doubled over earlier figures once researchers applied more rigorous, contemporary counting methods. Unfortunately, the trend continues upward, with prevalence climbing in every region of the world since 2013.In addition, MS is especially destructive because of its tendency to worsen progressively. Many patients initially experience a relapsing-remitting pattern, in which symptoms flare and then partially subside. Over time, however, a substantial share of patients shift into secondary progressive MS, a phase marked by steadily accumulating disability. According to the National MS Society, many people with MS end up juggling several medications at once, with each med addressing a separate symptom or relapse episode, yet none capable of confronting the underlying nerve damage that continues to erode their quality of life.The disease also imposes a substantial financial toll. The worldwide market for MS therapeutics was valued at roughly $27.4 billion in 2024 and is projected to climb to $38.62 billion by 2030, a trajectory driven not by curative treatments but by the sheer volume of patients requiring care across their lifetimes. That market dynamic highlights just how large the unmet need truly is. Patients require more than ongoing management; they need a therapy capable of interrupting the disease process itself.That is exactly the objective Quantum BioPharma has set out to achieve. The company is advancing Lucid-MS, a patented, first-in-class drug candidate unlike any therapy currently on the market, one engineered to act on the myelin sheath directly with the aim of preventing and protecting its breakdown.Acting Directly on the Myelin SheathThe majority of approved MS treatments function by modulating the immune system. They subdue or redirect the immune response responsible for attacking myelin, an approach that can lower relapse frequency and slow the buildup of disability. These therapies have delivered genuine clinical progress. Yet none of them directly address the myelin tissue itself or work to rebuild what has already been lost. For patients in the progressive stages of MS, immune modulation alone frequently proves inadequate.Lucid-MS charts an entirely separate course. Known technically as Lucid-21-302, the candidate is a patented New Chemical Entity, classified as a first-in-class, nonimmunomodulatory, neuroprotective compound. Instead of working through the immune system, Lucid-MS acts directly on the myelin sheath. In preclinical models, it has demonstrated the ability  to protect  myelin from degradation, a key pathological process  underlying multiple sclerosis. No currently approved treatment offers a comparable mechanism of action.A defining feature of Lucid-MS is that it does not impact immune function. That quality separates it from most existing MS therapies and may translate into a meaningful safety benefit. It also frames Lucid-MS not as a substitute for immune-modulating drugs but as a potential complement to them, or should future trial results support its early promise, as a foundational therapy in its own right. The drug is also being advanced in an oral form, which would offer patients greater convenience than the injectable or infusion-based treatments many currently rely on.Quantum BioPharma controls exclusive global rights to Lucid-MS through its wholly owned subsidiary, Lucid Psycheceuticals Inc. The program is guided by a top-tier scientific team that includes advisor Dr. Lakshmi P. Kotra, recipient of the Julia Levy Award, a senior scientist at the University Health Network and a professor of medicinal chemistry at the University of Toronto. The scientific team also includes Dr. Andrzej Chruscinski, vice president of Scientific and Clinical Affairs, whose career spans Stanford-trained internal medicine alongside cardiology and neurological research. This group is working toward something no approved drug has yet accomplished: an MS therapy that directly safeguards myelin.From Laboratory Findings to Human StudiesThe scientific case behind Lucid-MS rests on years of disciplined research. The compound has undergone study for upward of a decade, with findings published in some of medicine's most respected journals, including the "Journal of Medicinal Chemistry" and the "Proceedings of the National Academy of Sciences." These peer-reviewed papers track the compound's indicated capacity to prevent demyelination in preclinical settings.The animal-model results are notable. Across experiments carried out in multiple laboratories over the course of several years, Lucid-MS sped up functional recovery in mouse models of MS, preserved myelin integrity and reduced regional degradation. Documented results report that, following treatment, mice regain the capability to walk. This outcome did not stem from isolated experiments but from an extensive body of studies. The results proved compelling enough to justify advancing the compound into human trials.Quantum BioPharma presented its phase 1 clinical trial application for Lucid-MS to evaluate first-in-human safety and tolerability in 2023. The trial encompassed both Single Ascending Dose ("SAD") and Multiple Ascending Dose ("MAD") phases, which were administered among healthy volunteers. Results from the clinical study report identified no safety or tolerability concerns associated with daily dosing. Dosing in phase 1 among healthy human volunteers was successfully completed, with Lucid-MS characterized as exhibiting a favorable safety profile and good tolerability.Should upcoming phase 2 trials in MS patients confirm what the preclinical work suggested — that Lucid-MS can stop and prevent myelin degradation — it would represent an unprecedented milestone. No therapy currently approved for MS has shown the ability to help patients regain physical function previously lost to myelin damage. While human trials remain necessary to determine whether the preclinical results carry over to patients, a decade's worth of accumulated data provides a scientifically credible basis for that optimism.Submitting the IND, Preparing for Phase 2Late last year, the company finished dosing in both 180-day, repeated-dose oral toxicity and toxicokinetic studies for Lucid-21-302. These studies represent essential elements of the Investigational New Drug ("IND") application that the U.S. Food and Drug Administration ("FDA") requires before authorizing a phase 2 trial. Completing these extended safety studies marked a meaningful advance toward formal regulatory submission.The company additionally entered into agreements with a leading contract development and manufacturing organization to develop and produce an oral formulation of Lucid-MS, a critical step in preparing the drug for clinical use. Following that, in April this year, Quantum BioPharma officially filed its IND application with the FDA for Lucid-MS, aiming for a phase 2 trial designed to assess the therapy's efficacy, safety and tolerability among people living with MS.To carry out a phase 2 trial, Quantum BioPharma announced a binding letter of intent with Allucent, a global contract research organization with extensive experience running central nervous system trials. Quantum BioPharma also named a principal investigator for the upcoming trial, marking further progress in the clinical development program. These steps are indicative of an organization that has advanced methodically from encouraging preclinical results to taking the steps towards producing the human clinical data the MS community is waiting for.A Pioneering Partnership Sheds Light on the Path ForwardQuantum BioPharma is concurrently working with a tool that could prove vital to assessing Lucid-MS's effectiveness: an advanced imaging technique capable of directly visualizing myelin within the living human brain. Quantum BioPharma recently launched a joint clinical study with researchers at Massachusetts General Hospital ("MGH") to validate a novel positron emission tomography imaging method for tracking myelin integrity and demyelination in MS.The study centers on a PET tracer known as [¹8F]3F4AP, developed by Dr. Pedro Brugarolas, who is an investigator in the Department of Radiology at MGH and an assistant professor at Harvard Medical School. Dr. Eric Klawiter, director of the Multiple Sclerosis and Neuromyelitis Optica Unit at MGH and an associate professor of neurology at Harvard Medical School, is co-investigator on the project.In June of last year, the first patient with MS was scanned successfully, which marked the formal start of active patient enrollment. The MGH research team also published encouraging results in the "European Journal of Nuclear Medicine and Molecular Imaging," in a study funded by the National Institutes of Health. The tracer exhibited strong properties for brain imaging and, notably, was able to distinguish differences among lesions that conventional MRI could not detect. Last month, the study reached the midpoint of patient enrollment, with preliminary imaging results showing encouraging signal strength in acute MS lesions.The importance of this imaging work to Lucid-MS's development is difficult to overstate. One of the central challenges in developing any remyelinating therapy is confirming whether it is genuinely working, and conventional MRI cannot provide a direct, quantitative measure of myelin. Assuming it is validated, the [¹8F]3F4AP tracer could supply precisely that: a real-time biological window into how effectively a drug is protecting or restoring the myelin sheath.Chruscinski has noted that this tool has the potential to fundamentally reshape how demyelination is assessed, offering a direct view into axonal health and enabling clearer demonstration of how therapies such as Lucid-MS perform. This collaboration among the University Health Network, Massachusetts General Hospital and researchers affiliated with Harvard Medical School brings together world-class scientific expertise around a common purpose.Quantum BioPharma is laser focused on that objective. With the global MS therapeutics market projected to surpass $38 billion by 2030, the commercial stakes involved are substantial. Yet for the nearly three million people living with MS worldwide, what matters most is whether a therapy can finally achieve what none has accomplished before: Halting the disease, repairing the damage it causes and restoring the bodily control that MS has taken away. Should Lucid-MS fulfill its preclinical promise in human trials, it would represent more than a new drug; it would mark a genuine turning point.Advancing Treatment Options Across SectorsRecent developments across the biopharmaceutical industry highlight continued momentum in the development of therapies for autoimmune, immune-mediated and chronic inflammatory diseases. Companies are reporting encouraging clinical results, expanding development programs and achieving important regulatory milestones as they work to address conditions that can significantly impact quality of life and often remain difficult to treat.Novartis AG (NYSE: NVS) presented data from the RemIND trial at the European Academy of Allergy and Clinical Immunology ("EAACI") Congress. The data showed that Rhapsido(R) (remibrutinib) met its primary endpoints across the three most common chronic inducible urticaria (CIndU) subtypes, becoming the first-ever treatment to demonstrate efficacy in a global Phase III CIndU clinical trial. In the RemIND trial, higher rates of complete responses were observed at week 12, with responses seen as early as week 2 in two subtypes. These results demonstrate that Rhapsido may provide sustained relief for patients whose disease remains inadequately controlled after treatment with second-generation H1-antihistamines.Merck & Co. Inc. NYSE: MRK) announced positive topline results from the phase 3 ATLAS-UC induction-only study (study 2). The study evaluated tulisokibart ("MK-7240"), an investigational humanized monoclonal antibody targeting tumor necrosis factor-like cytokine 1A ("TL1A"), in patients with moderately to severely active UC. The study successfully met its primary endpoint of clinical remission according to the Modified Mayo Score at week 12, as well as key secondary endpoints. In addition, consistent with previously reported phase 2 studies, no safety concerns were identified.TG Therapeutics Inc. (NASDAQ: TGTX) reported positive topline phase 1 data for subcutaneous BRIUMVI in patients with myasthenia gravis. The company also announced theinitiation of a phase 2 clinical trial evaluating BRIUMVI as a maintenance therapy following induction with efgartigimod in adult patients with MG. The company noted that the encouraging results support continued development of BRIUMVI in MG and also mark an important milestone in expanding the potential utility of BRIUMVI beyond multiple sclerosis.Bristol Myers Squibb Company (NYSE: BMY) announced that the European Commission has approved Opdivo(R) (nivolumab) in combination with doxorubicin, vinblastine and dacarbazine for the treatment of adult and adolescent patients 12 years of age and older with previously untreated stage 3 or 4 classical Hodgkin lymphoma. This approval marks a significant milestone, establishing the Opdivo plus AVD combination as the first immunotherapy-based regimen available in the European Union for newly diagnosed advanced cHL.As scientific understanding of immune system dysfunction continues to evolve, researchers are uncovering new therapeutic targets and refining treatment strategies across a broad range of diseases. These efforts reflect a growing focus on delivering therapies that offer greater efficacy, convenience and durability while helping address substantial unmet medical needs.For further information about Quantum BioPharma Ltd., visit the Quantum BioPharma profile.About BioMedWireBioMedWire ("BMW") is a specialized communications platform with a focus on the latest developments in the Biotechnology (BioTech), Biomedical Sciences (BioMed) and Life Sciences sectors. It is one of 75+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today's market, BMW brings its clients unparalleled recognition and brand awareness.BMW is where breaking news, insightful content and actionable information converge.To receive SMS alerts from BioMedWire, "Biotech" to 888-902-4192 (U.S. Mobile Phones Only)For more information, please visit https://www.BioMedWire.comDISCLAIMER: BioMedWire (BMW) is the source of the Article and content set forth above. References to any issuer other than the profiled issuer are intended solely to identify industry participants and do not constitute an endorsement of any issuer and do not constitute a comparison to the profiled issuer. The commentary, views and opinions expressed in this release by BMW are solely those of BMW. Readers of this Article and content agree that they cannot and will not seek to hold liable BMW for any investment decisions by their readers or subscribers. BMW is a news dissemination and financial marketing solutions provider and are NOT registered broker-dealers/analysts/investment advisers, hold no investment licenses and may NOT sell, offer to sell or offer to buy any security.The Article and content related to the profiled company represent the personal and subjective views of the Author and are subject to change at any time without notice. The information provided in the Article and the content has been obtained from sources which the Author believes to be reliable. However, the Author has not independently verified or otherwise investigated all such information. None of the Author, BMW, or any of their respective affiliates, guarantee the accuracy or completeness of any such information. This Article and content are not, and should not be regarded as investment advice or as a recommendation regarding any particular security or course of action; readers are strongly urged to speak with their own investment advisor and review all of the profiled issuer's filings made with the Securities and Exchange Commission before making any investment decisions and should understand the risks associated with an investment in the profiled issuer's securities, including, but not limited to, the complete loss of your investment.BMW HOLDS NO SHARES OF ANY COMPANY NAMED IN THIS RELEASE.This release contains "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E the Securities Exchange Act of 1934, as amended and such forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. "Forward-looking statements" describe future expectations, plans, results, or strategies and are generally preceded by words such as "may", "future", "plan" or "planned", "will" or "should", "expected," "anticipates", "draft", "eventually" or "projected". You are cautioned that such statements are subject to a multitude of risks and uncertainties that could cause future circumstances, events, or results to differ materially from those projected in the forward-looking statements, including the risks that actual results may differ materially from those projected in the forward-looking statements as a result of various factors, and other risks identified in a company's annual report on Form 10-K or 10-KSB and other filings made by such company with the Securities and Exchange Commission. You should consider these factors in evaluating the forward-looking statements included herein and not place undue reliance on such statements. The forward-looking statements in this release are made as of the date hereof and BMW undertakes no obligation to update such statements.Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: https://www.BioMedWire.com/DisclaimerBioMedWire
Austin, Texas
www.BioMedWire.com
512.354.7000 Office
Editor@BioMedWire.comBioMedWire is powered by IBN Original: The Quest to Repair What Multiple Sclerosis Takes Away

$3.77

$4.20

$9.24
Pretty good.
Though the bottom at $2.07 from $14 was manipulated and uncalled for.

$9.60s after hours on Friday.

$7.81 — (even for the day)

$7.685

$8.20+ 😃

$QNTM 💹

Quantum BioPharma Shares Climb as Multiple Sclerosis Imaging Study Advances (QNTM)May 18, 2026 10:37 AM
IH Market News Stock Gains After Enrollment Milestone Reached Shares of Quantum BioPharma (NASDAQ:QNTM) rose 10% in premarket trading on Monday after the company announced that patient enrollment in its collaborative imaging study with Massachusetts General Hospital has reached the halfway stage, alongside encouraging early imaging findings. Study Focuses on Advanced Multiple Sclerosis Imaging The study aims to validate a positron emission tomography (PET) imaging method designed to directly evaluate demyelinated neurons with intact axons and monitor demyelination progression in patients with multiple sclerosis.The research uses the PET tracer [¹8F]3F4AP, which was developed by Pedro Brugarolas, an investigator in the Department of Radiology at Massachusetts General Hospital and Assistant Professor at Harvard Medical School. Preliminary Imaging Results Show Positive Signals According to the company, the initial participant group has successfully undergone imaging using both advanced PET/MR systems and total-body PET platforms.Early analysis reportedly showed strong imaging signals in acute multiple sclerosis lesions and suggested potential sensitivity in detecting gray matter lesions as well.“We are excited to reach this important midpoint in our study with MGH and encouraged by the strength of the preliminary imaging data,” said Dr. Andrzej Chruscinski, Vice-President, Scientific and Clinical Affairs at Quantum BioPharma. Technology Could Improve Evaluation of MS Therapies Quantum BioPharma said the imaging technology may allow researchers to more accurately measure how therapies affect myelin preservation and regeneration.The company believes the approach could strengthen evaluation of treatments such as its experimental candidate Lucid-MS (Lucid-21-302). Lucid-MS Targets Myelin Protection Lucid-MS is being developed as a neuroprotective therapy designed to inhibit demyelination by targeting protein arginine deiminase 2 (PAD2), an enzyme associated with myelin degradation.Quantum BioPharma submitted an Investigational New Drug application to the FDA in March 2026 seeking approval to begin Phase 2 clinical testing.The company added that earlier Phase 1 studies showed Lucid-MS demonstrated a favorable safety profile and was well tolerated in healthy participants.Quantum BioPharma stock price Original: Quantum BioPharma Shares Climb as Multiple Sclerosis Imaging Study Advances (QNTM)

$7.50+ 😃

=================

QNTM Institutional Holdings
Ownership Summary
Institutional Ownership | 4.38%
Total Shares Outstanding (millions) | 6
Total Value of Holdings (millions) | $2

Active Positions | Holders | Shares
Increased Positions | 15 | 141,327
Decreased Positions | 6 | 13,272
Held Positions | 10 | 100,820
Total Institutional Shares | 31 | 255,419

https://www.nasdaq.com/market-activity/stocks/qntm/institutional-holdings

=================

Quantum BioPharma (QNTM) Price Target Increased by 10.88% to 36.72

April 28, 2026

The average one-year price target for Quantum BioPharma (NasdaqCM:QNTM) has been revised to $36.72 / share. This is an increase of 10.88% from the prior estimate of $33.12 dated April 14, 2026.

The price target is an average of many targets provided by analysts. The latest targets range from a low of $36.36 to a high of $37.80 / share. The average price target represents an increase of 725.15% from the latest reported closing price of $4.45 / share.

What is the Fund Sentiment?
There are 26 funds or institutions reporting positions in Quantum BioPharma. This is an increase of 7 owner(s) or 36.84% in the last quarter. Average portfolio weight of all funds dedicated to QNTM is 0.00%, an increase of 98.76%. Total shares owned by institutions increased in the last three months by 60.24% to 169K shares.

What are Other Shareholders Doing?
AdvisorShares Investments holds 50K shares representing 0.85% ownership of the company. In its prior filing, the firm reported owning 37K shares , representing an increase of 24.98%. The firm decreased its portfolio allocation in QNTM by 39.39% over the last quarter.

Platform Technology Partners holds 41K shares representing 0.71% ownership of the company.

Citadel Advisors holds 16K shares representing 0.27% ownership of the company.

Marex Group holds 13K shares representing 0.23% ownership of the company. No change in the last quarter.

Gts Securities holds 12K shares representing 0.21% ownership of the company.

Fintel is one of the most comprehensive investing research platforms available to individual investors, traders, financial advisors, and small hedge funds.

Our data covers the world, and includes fundamentals, analyst reports, ownership data and fund sentiment, options sentiment, insider trading, options flow, unusual options trades, and much more. Additionally, our exclusive stock picks are powered by advanced, backtested quantitative models for improved profits.

This story originally appeared on Fintel.

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

Link article

$QNTM 💹

Quantum BioPharma Reaches Key Midpoint Milestone in Groundbreaking Imaging Study with Massachusetts General Hospital

May 18, 2026

Quantum BioPharma (NASDAQ: QNTM) reported a key midpoint milestone in its collaborative PET imaging study with Massachusetts General Hospital, with patient enrollment at 50% and encouraging preliminary imaging data.

The study uses novel tracer [¹8F]3F4AP to quantify demyelination in multiple sclerosis and support development of Quantum’s investigational therapy Lucid-MS, which showed favorable Phase 1 safety and preclinical myelin-protective effects. An IND for a Phase 2 trial was submitted to the FDA in March 2026.

Positive
• Patient enrollment at midpoint in MGH collaborative PET imaging study
• Preliminary PET data show robust signal in acute MS lesions
• [¹8F]3F4AP previously showed high sensitivity to demyelinated lesions
• Lucid-MS demonstrated favorable safety and tolerability in Phase 1 trials
• Lucid-MS preclinical models showed prevention and reversal of myelin breakdown
• IND for Lucid-MS Phase 2 trial submitted to FDA in March 2026

Negative
None

Promising Early Data Strengthens Potential of Novel PET Technology to Advance Development of Lucid-MS for Multiple Sclerosis

TORONTO, May 18, 2026 (GLOBE NEWSWIRE) -- Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) (FRA: 0K91) (“Quantum” or the “Company”), a biopharmaceutical company focused on advancing innovative therapies and technologies, today announced a significant milestone in its collaborative study with Massachusetts General Hospital (MGH): patient enrollment has reached the halfway mark, accompanied by encouraging preliminary imaging results. This pioneering study is designed to validate a novel positron emission tomography (PET) imaging technique capable of directly assessing demyelinated neurons with intact axons and tracking demyelination in patients with multiple sclerosis (MS)—a critical step toward transforming how disease progression and treatment response are measured.

At the center of this effort is the PET tracer [¹8F]3F4AP, developed by Pedro Brugarolas, an investigator in the Department of Radiology at MGH and Assistant Professor at Harvard Medical School. In prior preclinical and clinical studies, [¹8F]3F4AP demonstrated high sensitivity for detecting demyelinated lesions along with favorable pharmacokinetics, positioning it as a promising biomarker for monitoring myelin damage and repair.

Importantly, early data from the ongoing study reinforce this potential. The first cohort of participants has been successfully imaged using both advanced PET/MR and total-body PET platforms. Preliminary analyses indicate robust signal in acute MS lesions and potential sensitivity to gray matter lesions.

If validated, this imaging approach could represent a major advancement in MS research and drug development—enabling more precise, real-time measurement of how therapies impact myelin preservation and regeneration. Such capabilities may significantly enhance the evaluation of next-generation treatments, including Quantum’s investigational candidate, Lucid-MS (Lucid-21-302).

“We are excited to reach this important midpoint in our study with MGH and encouraged by the strength of the preliminary imaging data,” said Dr. Andrzej Chruscinski, Vice-President, Scientific and Clinical Affairs at Quantum BioPharma. “PET imaging with [¹8F]3F4AP has the potential to fundamentally change how we assess demyelination—providing a direct window into axonal health and enabling us to more clearly demonstrate the impact of therapies like Lucid-MS that aim to protect and restore the myelin sheath in MS.”

“From a scientific perspective, the ability to directly quantify demyelinated lesions with intact axons in vivo represents an important unmet need in multiple sclerosis research,” said Dr. Pedro Brugarolas of Massachusetts General Hospital. “If further validated, this imaging approach could provide a more direct and quantitative measure of myelin loss and repair, which may help improve the evaluation of disease mechanisms and therapeutic response in MS.”

Looking ahead, the Company believes that this novel biomarker platform could play a pivotal role in accelerating the development of effective treatments for MS such as Lucid-MS by delivering more accurate and actionable insights into disease activity over time.

Lucid-MS is designed to provide neuroprotection through the inhibition of demyelination—a key driver of disease progression in MS. This innovative mechanism represents a differentiated therapeutic approach in the global MS market, where most existing therapies focus primarily on modulating the immune response rather than addressing the underlying neurodegeneration. By targeting protein arginine deiminase 2 (PAD2), a key enzyme implicated in myelin degradation, Lucid-MS has demonstrated in preclinical models the ability to prevent and reverse myelin breakdown—offering the potential for a truly disease-modifying therapy in an indication with limited options.

The Phase 2 clinical trial will evaluate the efficacy, safety, and tolerability of Lucid-MS in people with MS. In prior Phase 1 clinical trials, Lucid-MS demonstrated a favorable safety profile and was well-tolerated in healthy participants, providing a strong foundation for continued development. The successful completion of Phase 1 supports advancement into this next pivotal study, which is designed to generate meaningful clinical data across both clinical and radiological endpoints. The IND submission for Phase 2 approval has been submitted to the FDA in March 2026.

About Quantum BioPharma Ltd.
Quantum is a biopharmaceutical company dedicated to building a portfolio of innovative assets and biotech solutions for the treatment of challenging neurodegenerative and metabolic disorders and alcohol misuse disorders with drug candidates in different stages of development. Through its wholly owned subsidiary, Lucid Psycheceuticals Inc. (“Lucid”), Quantum is focused on the research and development of its lead compound, Lucid-MS. Lucid-MS is a patented new chemical entity shown to prevent and reverse myelin degradation, the underlying mechanism of multiple sclerosis, in preclinical models. Quantum invented UNBUZZD™ and spun out its OTC version to a company, Unbuzzd Wellness Inc. (“Unbuzzd”) (formerly, Celly Nutrition Corp.), led by industry veterans. Quantum retains ownership of 19.84% (as of March 31, 2026) of Unbuzzd at www.unbuzzd.com. The agreement with Unbuzzd also includes royalty payments of 7% of sales from unbuzzd™ until payments to Quantum total $250 million. Once $250 million is reached, the royalty drops to 3% in perpetuity. Quantum retains 100% of the rights to develop similar products or alternative formulations specifically for pharmaceutical and medical uses.

Forward Looking Information
This news release contains “forward-looking information” and “forward-looking statements” within the meaning of applicable Canadian and United States securities laws (collectively, “forward-looking statements”). Forward-looking statements in this release include, but are not limited to, statements regarding: the continued advancement and completion of the collaborative imaging study with Massachusetts General Hospital (“MGH”); the potential validation and future utility of the [¹8F]3F4AP PET imaging technique; the ability of the imaging platform to assess demyelination, myelin integrity and treatment response in multiple sclerosis (“MS”); the potential application of the imaging technology in future clinical trials and drug development programs; the therapeutic potential, efficacy, safety, and development of Lucid-MS (Lucid-21-302); the anticipated initiation, timing, design, regulatory progress, and outcomes of the Company’s planned Phase 2 clinical trial; the review of the Company’s IND submission by the U.S. Food and Drug Administration (“FDA”); and the potential for Lucid-MS to become a disease-modifying therapy for MS.

Forward-looking statements are frequently identified by words such as “expects”, “anticipates”, “believes”, “intends”, “plans”, “may”, “will”, “could”, “potential”, “continue”, “aims”, “designed”, and similar expressions intended to identify forward-looking statements.

These forward-looking statements are based on management’s current expectations, assumptions, and beliefs, including assumptions relating to: the continued progression of the MGH imaging study; the reproducibility and clinical relevance of preliminary imaging data; the ability of the Company to continue advancing Lucid-MS through clinical development; the availability of funding and resources; favorable regulatory interactions and approvals; and the continued advancement of scientific and clinical research relating to MS and demyelinating diseases.

Forward-looking statements involve known and unknown risks, uncertainties, and other factors that may cause actual results, performance, or achievements to differ materially from those expressed or implied herein. Such risks and uncertainties include, among others: the possibility that preliminary imaging results may not be replicated in larger patient populations; risks associated with clinical trial enrollment, timing, delays, costs, or outcomes; uncertainty regarding regulatory approvals, including FDA review of the IND submission; scientific and technological uncertainties; changes in market conditions or competitive developments; the Company’s ability to obtain additional financing; and risks relating to the biotechnology and pharmaceutical industries generally.

Readers are cautioned not to place undue reliance on forward-looking statements, as actual results may differ materially from those expressed or implied by such statements. Although the Company believes that the assumptions and expectations reflected in the forward-looking statements are reasonable as of the date of this news release, no assurance can be given that such assumptions or expectations will prove to be correct.

The forward-looking statements contained in this news release are expressly qualified in their entirety by this cautionary statement and are made as of the date hereof. The Company undertakes no obligation to update or revise any forward-looking statements contained herein, whether as a result of new information, future events or otherwise, except as required by applicable securities laws.

Contacts:
Quantum BioPharma Ltd.
Zeeshan Saeed, Founder, CEO and Executive Co-Chairman of the Board
Email: Zsaeed@quantumbiopharma.com
Telephone: (833) 571-1811

Link article

$QNTM 🗞️

$6.70+ 😃

$QNTM 💹

QNTM...........................https://stockcharts.com/sc3/ui/?s=QNTM&p=w&b=5&g=0&id=p86431144783

Movin on up !!!!!

$3.08-

$4.28-

First signs of moving back up.

$6.35+ 😃

=====================

Why did QNTM stock pop in pre-market today?

March 30, 2026

Shares of Quantum BioPharma (QNTM) surged 15% in pre-market trading on Monday after the biotech firm signed a binding agreement with Allucent to support a planned Phase 2 trial of its Lucid-MS therapy for multiple sclerosis.

The study will evaluate the drug’s safety, effectiveness, and tolerability, with initiation expected in the second quarter of 2026, Quantum BioPharma said.

Lucid-MS is designed to protect nerves by targeting Demyelination, a key factor for multiple sclerosis progression. Allucent will provide end-to-end support for the clinical trial, including execution and data management.

“This innovative mechanism represents a differentiated therapeutic approach in the global MS market where an estimated 2.8 million people suffer and where many existing treatments primarily focus on modulating the immune system rather than addressing the underlying neurodegeneration,” said Andrzej Chruscinski, VP, Scientific and Clinical Affairs at Quantum BioPharma.

Get updates to this developing story on Stocktwits.

For updates and corrections, email newsroom[at]stocktwits[dot]com.

Link article

$QNTM 💹

$5.40+ 😃

$QNTM 💹

$4.95+ 😃

============

Quantum Biopharma’s 2025 Audited Year End Financial Results Maintain ‘No Going Concern’ Status

March 27, 2026

Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) (FRA: 0K91) (“Quantum” or the “Company”), has reported its audited financial and operational results for the fourth quarter and year ended December 31, 2025.

Fourth Quarter and Full Year 2025 Financial Results
Quantum’s strong balance sheet and overall progress continue, and management is confident that there is sufficient working capital, as of the date of filing these Financial Statements, to carry out its operations over the next 24 months. Cash on hand and fair market value of digital assets as of the date of filing these Financial Statements is $11.3 million USD. Management believes there is sufficient cash to sustain basic operations beyond January 2028. Digital assets continue to be used as a treasury function of the Company to allow diversification with high liquidity. The Company's ability to secure financing from multiple distinct sources in 2025, ranging from convertible debt, institutional loans, and the monetization of its loan portfolio, reflects a material improvement in capital market access and funding flexibility compared to the prior year.

For the year ended December 31, 2025, Operating Expenses were reduced to $15.3 million USD compared to $16.1 million USD in the same period of 2024, an improvement of approximately 5%.

As of the date of filing, the Company had reduced trade and other payables by approximately 50%, from $4.1 million on December 31, 2025, to $2.0 million, reflecting improved working capital management.

For the year ended December 31, 2025, external research and development fees decreased to $2.8 million USD compared to $6.1 million USD in the same period of 2024 as a result of phase 1 clinical trials ending, as well as R&D tax credit initiatives provided by the Australian government during FY2025.

For the year ended December 31, 2025, General and Administrative expenses decreased to $9.0 million USD compared to $9.4 million USD in the same period of 2024 as a result of operational efficiencies.

Full article

$QNTM 🗞️ 💹

$4.70+ 😃

$QNTM 💹

$3.80+ 😃

===================

Quantum Biopharma Ltd. Announces Peer-Reviewed Publication of Clinical Trial Results for Unbuzzd

March 24, 2026

Quantum BioPharma Ltd. announced the peer-reviewed publication of the double-blind, randomized, placebo-controlled crossover design clinical trial (NCT06505239) of its dietary supplement product, ?unbuzzd?, comprising of a proprietary blend of vitamins and supplements developed by a world-class team of scientists at Quantum BioPharma. The trial, which investigated the effects of unbuzzd on alcohol intoxication and alcohol metabolism, was published in the World Journal of Pharmaceutical and Medical Research (2026, volume 12, issue 3, pages 446-467). The clinical trial, designed to mirror real-life situations where people would consume unbuzzd after reaching an alcohol inebriated state included healthy male and female study participants between the ages of 21 and 43, with weights ranging from 119 to 232 pounds.

Participants first drank measured quantities of alcohol to achieve a Blood Alcohol Concentration (?BAC?) between 0.07% and 0.11% followed by ingestion of either unbuzzd or placebo. BAC was then further monitored as well as vital signs and symptoms of intoxication. unbuzzd accelerated the rate at which BAC was reduced in participants, while simultaneously reducing the symptoms of intoxication, impairment and hangover.

These results were statistically significant compared to placebo. Key findings from the clinical trial include: Accelerated Alcohol Metabolism: unbuzzd dramatically and rapidly reduced blood alcohol concentration in study participants. The rate at which BAC was lowered was on average for most participants more than 40% faster within the first 30 minutes of consuming unbuzzd compared to when participants consumed placebo.

The faster reduction of BAC after consuming unbuzzd was statistically significant compared to the placebo and was observed in both males and females (note: FSD-F2R6 is the scientific name of the unbuzzd formulation). The continued acceleration of alcohol metabolism was also seen at subsequent BAC measurements over a four-hour period. Rapid Improvements in Alertness: Study participants reported statistically significant improvement in alertness as soon as 30 minutes after consuming unbuzzd.

Participants felt more alert making fewer cognitive errors within 30 minutes of consuming unbuzzd, significantly outperforming placebo results. Rapid Improvements in Physiologic Changes due to Intoxication: unbuzzd lessened the elevation in heart rate and the drop in blood pressure that often accompanies alcohol intoxication, stabilizing both. This result was noted as statistically significant.

Reduced Perceived Impairment and Mental Fatigue: unbuzzd helped alleviate perceived impairment and mental fatigue caused by alcohol intoxication. Hangover Relief: Participants in this study noted a statistically significant reduction in hangover symptoms. This included reduced cognitive and physical impairment, and reduced headache compared to placebo results, at both four hours (67% reduction in headache severity) and eight hours after consuming unbuzzd. No Side Effects: unbuzzd was well-tolerated by all study participants, with no reported adverse side effects.

The formula for unbuzzd is licensed to Unbuzzd Wellness Inc. and is currently available at www.unbuzzd.com and www.amazon.com. unbuzzd is a registered trademark of Unbuzzd Wellness Inc. Individual results may vary. unbuzzd is a dietary supplement.

Consuming unbuzzd after alcohol ingestion does not permit you to operate a vehicle. Drink responsibly. DO NOT DRINK AND DRIVE.

unbuzzd ready-to-mix powder sticks are available in 3-pack, 8-pack, and 18-pack formats at https://unbuzzd.com. Individual results may vary. unbuzzd is a dietary supplement.

Consuming unbuzzd after alcohol ingestion does not permit you to operate a vehicle. Drink responsibly. DO NOT DRINK AND DRIVE.

Quantum BioPharma invented UNBUZZD? and spun out its OTC version to a company, Unbuzzd Wellness Inc. (UWI), led by industry veterans. Quantum BioPharma retains ownership of 19.86% (as of September 30, 2025) of UWI at www.unbuzzd.com.

The agreement with UWI also includes royalty payments of 7% of sales from unbuzzd? until payments to Quantum BioPharma total $250 million. Once $250 million is reached, the royalty drops to 3% in perpetuity.

Additionally, Quantum BioPharma retains a large tax loss carry forward of approximately CAD 130 million and could be utilized in the future to offset tax payable obligations against future profits. Quantum BioPharma retains 100% of the rights to develop similar product or alternative formulations specifically for pharmaceutical and medical uses. Quantum BioPharma maintains a portfolio of strategic investments through its wholly owned subsidiary, FSD Strategic Investments Inc., which represents loans secured by residential or commercial property.

Link article

$QNTM 🗞️ 🤓

Quantum BioPharma Announces Peer-Reviewed Journal Publication of Groundbreaking Clinical Trial With Unbuzzd

March 23, 2026

Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) (FRA: 0K91) (“Quantum BioPharma” or the “Company”), "Company"), a biopharmaceutical company dedicated to building a portfolio of innovative assets and biotech solutions, announced the peer-reviewed publication of the double-blind, randomized, placebo-controlled crossover design clinical trial (NCT06505239) of its dietary supplement product, ‘unbuzzd’, comprising of a proprietary blend of vitamins and supplements developed by a world-class team of scientists at Quantum BioPharma. The trial, which investigated the effects of unbuzzd on alcohol intoxication and alcohol metabolism, was published here in the World Journal of Pharmaceutical and Medical Research (2026, volume 12, issue 3, pages 446-467).

The publication can be viewed by clicking the following link: https://zenodo.org/records/18873638

The clinical trial, designed to mirror real-life situations where people would consume unbuzzd after reaching an alcohol inebriated state included healthy male and female study participants between the ages of 21 and 43, with weights ranging from 119 to 232 pounds. Participants first drank measured quantities of alcohol to achieve a Blood Alcohol Concentration (“BAC”) between 0.07% and 0.11% followed by ingestion of either unbuzzd or placebo. BAC was then further monitored as well as vital signs and symptoms of intoxication. unbuzzd accelerated the rate at which BAC was reduced in participants, while simultaneously reducing the symptoms of intoxication, impairment and hangover. These results were statistically significant compared to placebo.

Key findings from the clinical trial include:

• Accelerated Alcohol Metabolism: unbuzzd dramatically and rapidly reduced blood alcohol concentration in study participants. The rate at which BAC was lowered was on average for most participants more than 40 percent faster within the first 30 minutes of consuming unbuzzd compared to when participants consumed placebo.

• The faster reduction of BAC after consuming unbuzzd was statistically significant compared to the placebo and was observed in both males and females as shown in the figure below from the publication (note: FSD-F2R6 is the scientific name of the unbuzzd formulation). The continued acceleration of alcohol metabolism was also seen at subsequent BAC measurements over a four-hour period.

• Rapid Improvements in Alertness: Study participants reported statistically significant improvement in alertness as soon as 30 minutes after consuming unbuzzd. Participants felt more alert making fewer cognitive errors within 30 minutes of consuming unbuzzd, significantly outperforming placebo results.

• Rapid Improvements in Physiologic Changes due to Intoxication: unbuzzd lessened the elevation in heart rate and the drop in blood pressure that often accompanies alcohol intoxication, stabilizing both. This result was noted as statistically significant.

• Reduced Perceived Impairment and Mental Fatigue: unbuzzd helped alleviate perceived impairment and mental fatigue caused by alcohol intoxication.

• Hangover Relief: Participants in this study noted a statistically significant reduction in hangover symptoms. This included reduced cognitive and physical impairment, and reduced headache compared to placebo results, at both four hours (67 percent reduction in headache severity) and eight hours after consuming unbuzzd.

• No Side Effects: unbuzzd was well-tolerated by all study participants, with no reported adverse side effects.

“The unbuzzd clinical trial has now been published in a peer-reviewed international journal, and the trial confirms the exceptional overall efficacy of unbuzzd to help reduce the acute effects of alcohol intoxication and hangover, all without causing adverse side effects,” said Dr. Andrzej Chruscinski, Vice President of Clinical and Scientific Affairs at Quantum Biopharma. “We are thrilled to report this outcome.”

Anthony Durkacz, Founder and Executive Co-Chairman of Quantum BioPharma added, “The science and medical communities for centuries have believed there is no way to significantly speed up alcohol metabolism once it is in your bloodstream; your liver processes it at a largely constant rate of approximately one standard drink per hour, and that the only sobering agent is time. This publication validates unbuzzd as a responsible aid to reduce BAC, alleviate signs of alcohol intoxication, and assists with the dreaded hangover. Consumers can use unbuzzd knowing there is a peer-reviewed scientific publication with clinical trial evidence of the product’s efficacy.”

The formula for unbuzzd is licensed to Unbuzzd Wellness Inc. and is currently available at www.unbuzzd.com and www.amazon.com. unbuzzd is a registered trademark of Unbuzzd Wellness Inc.

Individual results may vary. unbuzzd is a dietary supplement. Consuming unbuzzd after alcohol ingestion does not permit you to operate a vehicle. Drink responsibly. DO NOT DRINK AND DRIVE.

About Unbuzzd Wellness Inc.
Unbuzzd Wellness inc., a non-trading but fully reporting public issuer, stands as a pioneering force in the wellness and recovery supplement landscape. unbuzzd has been developed by a world-class R&D team in pharmacology and medicine, with a commitment to innovation and quality. A proprietary blend of vitamins, minerals, and herbs, unbuzzd helps your body process alcohol faster, restore mental alertness, and improve cognition so you can drink responsibly and drink refreshingly. unbuzzd appeals to a broad target audience of alcohol consumers who want to have a good time, be in control, and still feel great the next day.

unbuzzd ready-to-mix powder sticks are available in 3-pack, 8-pack, and 18-pack formats at https://unbuzzd.com.

Individual results may vary. unbuzzd is a dietary supplement. Consuming unbuzzd after alcohol ingestion does not permit you to operate a vehicle. Drink responsibly. DO NOT DRINK AND DRIVE.

About Quantum BioPharma Ltd.
Quantum BioPharma is a biopharmaceutical company dedicated to building a portfolio of innovative assets and biotech solutions for the treatment of challenging neurodegenerative and metabolic disorders and alcohol misuse disorders with drug candidates in different stages of development. Through its wholly owned subsidiary, Lucid Psycheceuticals Inc. (“Lucid”), Quantum BioPharma is focused on the research and development of its lead compound, Lucid-MS. Lucid-MS is a patented new chemical entity shown to prevent and reverse myelin degradation, the underlying mechanism of multiple sclerosis, in preclinical models. Quantum BioPharma invented UNBUZZD™ and spun out its OTC version to a company, Unbuzzd Wellness Inc. (“UWI”), led by industry veterans. Quantum BioPharma retains ownership of 19.86% (as of September 30, 2025) of UWI at www.unbuzzd.com. The agreement with UWI also includes royalty payments of 7% of sales from unbuzzd™ until payments to Quantum BioPharma total $250 million. Once $250 million is reached, the royalty drops to 3% in perpetuity. Additionally, Quantum BioPharma retains a large tax loss carry forward of approximately C$130 million and could be utilized in the future to offset tax payable obligations against future profits. Quantum BioPharma retains 100% of the rights to develop similar product or alternative formulations specifically for pharmaceutical and medical uses. Quantum BioPharma maintains a portfolio of strategic investments through its wholly owned subsidiary, FSD Strategic Investments Inc., which represents loans secured by residential or commercial property.

Forward-Looking Information
Certain information in this news release constitutes forward-looking statements under applicable securities laws. Any statements that are contained in this news release that are not statements of historical fact may be deemed to be forward-looking statements. Forward-looking statements are often identified by terms such as “may”, “should”, “anticipate”, “expect”, “potential”, “believe”, “intend” or the negative of these terms and similar expressions.

Readers are cautioned that the foregoing list is not exhaustive. Readers are further cautioned not to place undue reliance on forward-looking statements, as there can be no assurance that the plans, intentions or expectations upon which they are placed will occur. Such information, although considered reasonable by management at the time of preparation, may prove to be incorrect and actual results may differ materially from those anticipated.

Forward-looking statements contained in this press release are expressly qualified by this cautionary statement and reflect the Company’s expectations as of the date hereof and are subject to change thereafter. The Company undertakes no obligation to update or revise any forward-looking statements, whether as a result of new information, estimates or opinions, future events or results or otherwise or to explain any material difference between subsequent actual events and such forward- looking information, except as required by applicable law.

Contacts:
Quantum BioPharma Ltd.
Zeeshan Saeed, Founder, CEO and Executive Co-Chairman of the Board
Email: Zsaeed@quantumbiopharma.com
Telephone: (416) 854-8884

Investor Relations
Email: ir@quantumbiopharma.com, info@quantumbiopharma.com
Website: www.quantumbiopharma.com

Link article

🗞️ 🤓

Quantum BioPharma Provides Corporate Update - March 11th, 2026

THIS NEWS RELEASE IS INTENDED FOR DISTRIBUTION IN CANADA ONLY AND IS NOT INTENDED FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR DISSEMINATION IN THE UNITED STATES.

TORONTO, March 11, 2026 -- Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) (FRA: 0K91) (“Quantum BioPharma” or the “Company”), announces that further to its news release on March 10, 2026 (the “March 10 NR”), due to a decrease in the public market price of the Class B subordinate voting shares of the Company (each, a “Share”), the Company has revised the terms of the Debenture Units (as defined in the March 10 NR) as follows:

I. reduce the conversion price per Share to $3.00;
II. increase the number of Warrants (as defined in the March 10 NR) included as part of each Debenture Unit to 333.33;
and
III. reduce the exercise price per Warrant Share (as defined in the March 10 NR) to $3.75.

Furthermore, the Debt Settlement (as defined in the March 10 NR) will also be completed at the reduced conversion price.

All amounts in this press release are expressed in Canadian dollars.

The securities being offered have not been, nor will they be, registered under the United States Securities Act of 1933, as amended, and may not be offered or sold in the United States or to, or for the account or benefit of, U.S. persons absent registration or an applicable exemption from the registration requirements. This press release shall not constitute an offer to sell or the solicitation of an offer to buy nor shall there be any sale of the securities in any State in which such offer, solicitation or sale would be unlawful.

About Quantum BioPharma Ltd.
Quantum BioPharma is a biopharmaceutical company dedicated to building a portfolio of innovative assets and biotech solutions for the treatment of challenging neurodegenerative and metabolic disorders and alcohol misuse disorders with drug candidates in different stages of development. Through its wholly owned subsidiary, Lucid Psycheceuticals Inc. (“Lucid”), Quantum BioPharma is focused on the research and development of its lead compound, Lucid-MS. Lucid-MS is a patented new chemical entity shown to prevent and reverse myelin degradation, the underlying mechanism of multiple sclerosis, in preclinical models. Quantum BioPharma invented UNBUZZDTM and spun out its OTC version to a company, Celly Nutrition Corp. (“Celly Nutrition”), led by industry veterans. Quantum BioPharma retains ownership of 25.71% (as of June 30, 2024) of Celly Nutrition at www.unbuzzd.com. The agreement with Celly Nutrition also includes royalty payments of 7% of sales from unbuzzd TM until payments to Quantum BioPharma total $250 million. Once $250 million is reached, the royalty drops to 3% in perpetuity. Additionally, Quantum BioPharma retains a large tax loss carry forward of approximately C$130 million and could be utilized in the future to offset tax payable obligations against future profits. Quantum BioPharma retains 100% of the rights to develop similar product or alternative formulations specifically for pharmaceutical and medical uses. Quantum BioPharma maintains a portfolio of strategic investments through its wholly owned subsidiary, FSD Strategic Investments Inc., which represents loans secured by residential or commercial property.

Quantum BioPharma Provides Corporate Update - March 10th, 2026

THIS NEWS RELEASE IS INTENDED FOR DISTRIBUTION IN CANADA ONLY AND IS NOT INTENDED FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR DISSEMINATION IN THE UNITED STATES.

TORONTO, March 10, 2026 -- Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) (FRA: 0K91) (“Quantum BioPharma” or the “Company”), is pleased to announce that it will release its financial and operational results for the quarter and year ended December 31, 2025, after financial markets close on March 24, 2026. The Company’s fourth fiscal quarter and year end 2025 financial and operational results will be available on SEDAR+, EDGAR, and on the Company’s website at https://www.quantumbiopharma.com/investors.

Private Placement Offering
The Company also announces that it intends to complete a non-brokered private placement offering (the “Offering”) of up to 4,000 convertible debenture units (the “Debenture Units”) of the Company at a price of $1,000 per Debenture Unit.

Each Debenture Unit will consist of (i) one secured convertible debenture having a face value of $1,000.00 (each a “Debenture”); and (ii) 250 common share purchase warrants (each a “Warrant”) exercisable for 250 Class B subordinate voting shares in the Company (each, a “Share”). The Debentures will mature on the date that is 24 months from the date of issuance (the “Maturity Date”) and shall bear interest at a rate of 1.25% per month, beginning on the date of issuance and payable in cash on the last day of each calendar quarter, starting June 30, 2026.

The principal sum of the Debentures, or any portion thereof, and any accrued but unpaid interest, may be converted into Shares at a conversion price of $4.00 per Share (the “Conversion Price”). Each Warrant shall entitle the holder to acquire one additional Share (each, a “Warrant Share”) at a price of $5.00 per Warrant Share, for a period of five (5) years from the date of issuance.

The Company will use the proceeds from the Offering for the ongoing development of the Company’s business model and for general working capital purposes.

Debt Settlement
The Company also announces that it intends to settle certain amounts owing to arm’s length creditors and insiders of the Company (collectively, the “Creditors”) through the issuance of Shares at a deemed price per Share equal to the Conversion Price (the “Debt Settlement”).

The participation by insiders of the Company in the Debt Settlement constitutes a “related party transaction” as defined under Multilateral Instrument 61-101 – Protection of Minority Security Holders in Special Transactions (“MI 61-101”). The Company is relying on the exemptions from the formal valuation and minority shareholder approval requirements of MI 61-101 contained in sections 5.5(a) and 5.7(1)(a) of MI 61-101, as neither the fair market value of the subject matter of, nor the fair market value of the consideration for, the transaction exceeds 25% of the Company’s market capitalization, as determined in accordance with MI 61-101. The Company did not file a material change report in respect of the related party aspects of the Debt Settlement at least 21 days before the expected closing of the Debt Settlement, which the Company deems reasonable in the circumstances in order to expedite the completion of the Debt Settlement.

All amounts in this press release are expressed in Canadian dollars.
The securities being offered have not been, nor will they be, registered under the United States Securities Act of 1933, as amended, and may not be offered or sold in the United States or to, or for the account or benefit of, U.S. persons absent registration or an applicable exemption from the registration requirements. This press release shall not constitute an offer to sell or the solicitation of an offer to buy nor shall there be any sale of the securities in any State in which such offer, solicitation or sale would be unlawful.

For the first time since August, shares available to lend have disappeared. They're locking the float. Strong upside move soon!

QUANTUM BIO BEAST BOUNCE

After the last two days of this bloodbath with the stock down well over 30%, I think the CEO of both quantum and un buzzed wellness should be fired or resign!  Un buzzed wellness has been trying to raise $5 million for the last year and can’t do it. 

Quauntum is a bloodbath

Looks like Quantum is still being shorted.




Quantum Biopharma Ltd ($QNTM)

.

Massive upside alert!” QNTM trades ~$18.50, market cap ~$72M — from $2.70 low to $38.25 high. Jump in!

Spoofed Again. Manipulation again , every time there is an announcement, NEVER FAILS TO DROP, disgusting shorts . They will pay one of these days 

Announcement https://irreach.com/lt.php?c=79386&m=85187&nl=2096&s=b26e698e44b8e6100417fbc6f4af4cb1&lid=246352&l=-https--app.quotemedia.com/data/downloadFiling--Q-webmasterId--E-102691--A-ref--E-319457420--A-type--E-PDF--A-symbol--E-QNTM--A-cdn--E-2c2c7853488b55563247d334f5dab068--A-companyName--E-Quantum--PL-Biopharma--PL-Ltd.--A-formType--E-6-K--A-formDescription--E-Report--PL-of--PL-foreign--PL-private--PL-issuer--PL-pursuant--PL-to--PL-Rule--PL-13a-16--PL-or--PL-15d-16--PL-under--PL-the--PL-Securities--PL-Exchange--PL-Act--PL-of--PL-1934--A-dateFiled--E-2025-09-18

QNTM advancing global healthcare solutions

Go further, faster—$QNTM delivers growth without limits.

$QNTM Starting up

What merge ?

$QNTM Big Merge Alert

QNTM charts

Daily
https://schrts.co/rTazyTXM

Weekly
https://schrts.co/rWCziTHF


Looks like QNTM wants to go back up to 50s, 60s, maybe 70s.

Already stellar moves from $3.

Trust QNTM for cutting-edge biopharma solutions – innovation that improves and extends human life.

Quantum BioPharma Announces First Person with Multiple Sclerosis (MS) Scanned in Joint Study with Massachusetts General Hospital

June 17, 2025

https://ih.advfn.com/stock-market/NASDAQ/quantum-biopharma-QNTM/stock-news/96257758/quantum-biopharma-announces-first-person-with-mult

$QNTM

Sidoti Micro-Cap Conference



Daily Chart

Announcement 
https://ih.advfn.com/stock-market/NASDAQ/quantum-biopharma-QNTM/stock-news/95777897/quantum-biopharma-licensee-celly-nutrition-launche

looking to see 15s today - any opinion??

anyone in this?

Looks like a rally starting, Remember only 2.200,000 approx. shares outstanding ! ! Est. 17,000,00 SHORT INTREST.....

QNTM nice news this morning https://ih.advfn.com/stock-market/NASDAQ/quantum-biopharma-QNTM/stock-news/95515776/quantum-biopharma-announces-completion-of-the-phas

'Gail' has NO PROBLEM with having the entire PLANET EARTH know EVERYTHING about her, Bro --- it's all GOOD. (But, indeed, PAY-BACK any money anybody OWES to anybody!! Indeed, Sir!!)

PS: Gail's classic review of the original SPAM --- vs. Walmart's version thereof --- is the FUNNIEST thing in the entire HISTORY of FOOD!!!

well you were not suppose to expose the whole story...but a maggot like him that brags about making all this money in the market and does not pay her back...he deserves to be knocked out not praised...hes a lying pos and does not have a pot to piss in

QNTM: And it's STILL going UP!!! (Smart play by you, to grab it when down.)

QNTM: Hey, Dude, the ENTIRE story behind that Lady is absolutely BONKERS!!! (E.g., at 17 --- if her Mother had NOT stopped her --- she would likely have landed a role in TOM HANK's early sitcom. WHY? Because Gail's then high school pal --- who was already IN Hank's sitcom --- had invited Gail to Calif. to land another role therein!!!)

I've been riding free since $12 In at $6 but thanks ;)